retatrutide developer company Retatrutide: Phase 3 Results (Up to 28.7% Weight Loss), Mechanism, Trials & 2026 Updates Retatrutide (RETA-40) 107mg Research Peptide

She told TODAY that she had been on the medication for nearly a year and had lost 34 pounds

Let the water dissolve the powder naturally, or swirl the vial gently

The most common AEs of GLP-1RAs are gastrointestinal complaints, such as nausea, vomiting, constipation, and diarrhea

Monthly weight loss during this period often runs 4-6% of remaining body weight

The half-life is 5 days, and it is administered by subcutaneous injection once a week

Some researchers find the larger injection volumes less comfortable, especially for daily protocols, though retatrutide is administered weekly which makes this less of a concern